Phibro Animal Health Earnings Call Transcripts
Fiscal Year 2026
-
Strong quarterly growth was driven by broad portfolio performance and recent acquisitions, with continued margin expansion expected. Regulatory changes in Brazil will create short-term headwinds, but operational experience and new sustainability initiatives, including a carbon-negative feed additive, position the business for long-term growth.
-
Q3 2026 saw 10% sales growth and 11% higher Adjusted EBITDA, led by Animal Health. FY2026 guidance was raised across all key metrics, with regulatory and geopolitical risks incorporated. New sustainability initiatives and a leadership transition were highlighted.
-
Strong revenue and income growth were driven by the Zoetis MFA acquisition, robust vaccine and nutritional specialty performance, and positive market dynamics. Integration of the acquisition is nearly complete, with expanded geographic reach and enhanced customer offerings. Leadership transition will maintain strategic continuity.
-
Q2 saw 21% sales and 41% EBITDA growth, led by animal health and MFA integration. Fiscal 2026 guidance was raised for sales, EBITDA, and net income, reflecting strong demand and operational momentum. Leadership transition and new product launches support future growth.
-
Q1 2026 saw 40% sales growth and 102% adjusted EBITDA growth, driven by animal health and MFA integration. Fiscal 2026 guidance for EBITDA and net income was raised, with continued investment in innovation and companion animal expansion.
Fiscal Year 2025
-
Fiscal 2026 will see strong growth from the full-year Zoetis MFA portfolio, expanding vaccines and nutritional specialties, and the Phibro Forward initiative. Integration of the Zoetis deal has exceeded expectations, supporting margin gains and future investments. Vaccines and nutritional specialties are set to outpace overall market growth.
-
Q4 and FY2025 saw robust sales and EBITDA growth, led by Animal Health and the Zoetis MFA integration. FY2026 guidance projects continued double-digit growth, with Phibro Forward and full-year Zoetis contributions driving results.
-
A major acquisition expanded the product portfolio, geographic reach, and species coverage, driving strong sales and EBITDA growth. Integration has been smooth, with new opportunities in Europe and beef, and a focus on innovation and sustainability positioning the company for future growth.
-
Q3 2025 saw 32% sales growth and 85% adjusted EBITDA increase, led by animal health and the Zoetis MFA integration. Fiscal 2025 guidance was raised for EBITDA and EPS, with tariff impacts expected to be manageable and strong cash flow supporting ongoing investments.
-
Strong revenue and income growth followed the Zoetis MFA acquisition, with robust performance across all business segments. Strategic initiatives target further efficiency and growth, while positive industry trends and a diversified portfolio support an optimistic outlook.
-
Q2 saw 24% sales growth and 64% adjusted EBITDA growth, driven by strong Animal Health demand and the Zoetis MFA acquisition. Fiscal 2025 guidance was raised, with robust outlooks across all segments and minimal expected tariff impact.
-
Q1 net sales rose 13% year-over-year, with strong growth in animal health, mineral nutrition, and performance products. Standalone FY25 guidance calls for 3–8% revenue growth and 11–19% adjusted EBITDA growth, while the Zoetis acquisition is expected to add $200 million in revenue over eight months.
Fiscal Year 2024
-
Management outlined a multi-year growth strategy centered on core animal health, the accretive Zoetis MFA acquisition, and the Phibro Forward initiative to drive margin and income growth. Strong market demand, stable regulatory environment, and a balanced R&D approach support positive outlook into 2025 and beyond.
-
Q4 saw 7% sales growth, led by animal health and vaccines, while full-year sales rose 4%. Adjusted EBITDA and net income improved in Q4, but full-year GAAP results were impacted by FX losses. FY2025 guidance projects 2–7% sales growth, with Zoetis deal expected to close in Q4.